Rapt Therapeutics (NASDAQ:RAPT) Given New $27.00 Price Target at HC Wainwright

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) had its target price increased by equities research analysts at HC Wainwright to $27.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target indicates a potential upside of 209.63% from the stock's previous close.

A number of other research analysts have also recently commented on RAPT. Wall Street Zen cut shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. UBS Group dropped their price objective on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $19.80.

Rapt Therapeutics Trading Up 3.1%

NASDAQ:RAPT traded up $0.26 during trading hours on Thursday, reaching $8.72. The company had a trading volume of 38,798 shares, compared to its average volume of 109,644. The firm has a market cap of $144.23 million, a price-to-earnings ratio of -0.45 and a beta of -0.09. The firm's 50 day moving average price is $7.87 and its 200-day moving average price is $8.79. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $30.60.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.48) by $1.84. On average, analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rapt Therapeutics

A number of institutional investors have recently modified their holdings of the business. Checkpoint Capital L.P. acquired a new stake in shares of Rapt Therapeutics in the first quarter worth approximately $134,000. AQR Capital Management LLC acquired a new position in shares of Rapt Therapeutics in the 1st quarter valued at $188,000. ADAR1 Capital Management LLC grew its stake in shares of Rapt Therapeutics by 408.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock valued at $7,284,000 after buying an additional 4,796,455 shares during the period. Nantahala Capital Management LLC increased its holdings in shares of Rapt Therapeutics by 303.1% during the 1st quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock worth $6,116,000 after buying an additional 3,769,414 shares during the last quarter. Finally, Comerica Bank raised its position in shares of Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock worth $109,000 after buying an additional 31,287 shares during the period. 99.09% of the stock is owned by institutional investors and hedge funds.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.